title: A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
abstract: OBJECTIVE
  To evaluate the safety and efficacy of infliximab in the treatment of juvenile rheumatoid arthritis (JRA).
  
  
  METHODS
  This was an international, multicenter, randomized, placebo-controlled, double-blind study. One hundred twenty-two children with persistent polyarticular JRA despite prior methotrexate (MTX) therapy were randomized to receive infliximab or placebo for 14 weeks, after which all children received infliximab through week 44. Patients received MTX plus infliximab 3 mg/kg through week 44, or MTX plus placebo for 14 weeks followed by MTX plus infliximab 6 mg/kg through week 44.
  
  
  RESULTS
  Although a higher proportion of patients in the 3 mg/kg infliximab group than in the placebo group had achieved responses according to the American College of Rheumatology (ACR) Pediatric 30 (Pedi 30) criteria for improvement at week 14 (63.8% and 49.2%, respectively), the between-group difference in this primary efficacy end point was not statistically significant (P = 0.12). By week 16, after the crossover from placebo to infliximab 6 mg/kg when all patients were receiving infliximab, an ACR Pedi 30 response was achieved in 73.2% of all patients. By week 52, ACR Pedi 50 and ACR Pedi 70 responses had been reached in 69.6% and 51.8%, respectively, of patients. Infliximab was generally well tolerated, but the safety profile of infliximab 3 mg/kg appeared less favorable than that of infliximab 6 mg/kg, with more frequent occurrences of serious adverse events, infusion reactions, antibodies to infliximab, and newly induced antinuclear antibodies and antibodies to double-stranded DNA observed with the 3 mg/kg dose.
  
  
  CONCLUSIONS
  While infliximab at 3 mg/kg and 6 mg/kg showed durable efficacy at 1 year, achievement of the primary efficacy end point at 3 months did not differ significantly between infliximab-treated and placebo-treated patients. Safety data indicated that the 6-mg/kg dose may provide a more favorable risk/benefit profile. These results warrant further investigation in children with JRA.
authors.affiliation: IRCCS, Istituto G. Gaslini, Genoa, Italy. nicolaruperto@ospedale-gaslini.ge.it
authors.forename: Nicolino
authors.initials: N
authors.lastname: Ruperto
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Lovell
authors.forename: Ruben
authors.initials: R
authors.lastname: Cuttica
authors.forename: Nick
authors.initials: N
authors.lastname: Wilkinson
authors.forename: Patricia
authors.initials: P
authors.lastname: Woo
authors.forename: Graciela
authors.initials: G
authors.lastname: Espada
authors.forename: Carine
authors.initials: C
authors.lastname: Wouters
authors.forename: Earl D
authors.initials: ED
authors.lastname: Silverman
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Balogh
authors.forename: Michael
authors.initials: M
authors.lastname: Henrickson
authors.forename: Maria-Teresa
authors.initials: MT
authors.lastname: Apaz
authors.forename: Eileen
authors.initials: E
authors.lastname: Baildam
authors.forename: Anders
authors.initials: A
authors.lastname: Fasth
authors.forename: Valeria
authors.initials: V
authors.lastname: Gerloni
authors.forename: Pekka
authors.initials: P
authors.lastname: Lahdenne
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Prieur
authors.forename: Angelo
authors.initials: A
authors.lastname: Ravelli
authors.forename: Rotraud K
authors.initials: RK
authors.lastname: Saurenmann
authors.forename: Maria Luz
authors.initials: ML
authors.lastname: Gamir
authors.forename: Nico
authors.initials: N
authors.lastname: Wulffraat
authors.forename: Laszlo
authors.initials: L
authors.lastname: Marodi
authors.forename: Ross E
authors.initials: RE
authors.lastname: Petty
authors.forename: Rik
authors.initials: R
authors.lastname: Joos
authors.forename: Francesco
authors.initials: F
authors.lastname: Zulian
authors.forename: Deborah
authors.initials: D
authors.lastname: McCurdy
authors.forename: Barry L
authors.initials: BL
authors.lastname: Myones
authors.forename: Kalman
authors.initials: K
authors.lastname: Nagy
authors.forename: Peter
authors.initials: P
authors.lastname: Reuman
authors.forename: Ilona
authors.initials: I
authors.lastname: Szer
authors.forename: Suzanne
authors.initials: S
authors.lastname: Travers
authors.forename: Anna
authors.initials: A
authors.lastname: Beutler
authors.forename: Greg
authors.initials: G
authors.lastname: Keenan
authors.forename: Jason
authors.initials: J
authors.lastname: Clark
authors.forename: Sudha
authors.initials: S
authors.lastname: Visvanathan
authors.forename: Adedigbo
authors.initials: A
authors.lastname: Fasanmade
authors.forename: Aparna
authors.initials: A
authors.lastname: Raychaudhuri
authors.forename: Alan
authors.initials: A
authors.lastname: Mendelsohn
authors.forename: Alberto
authors.initials: A
authors.lastname: Martini
authors.forename: Edward H
authors.initials: EH
authors.lastname: Giannini
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab; D008727:Methotrexate